EZCyp™ Active Human Cytochrome P450 2C9 | 7875

Cytochrome P450 2C9 (CYP2C9, EC 1.14.14.1) is a member of the cytochrome P450 monooxidase (CYP) family of microsomal xenobiotic metabolism enzymes. CYPs are membrane-bound hemeproteins responsible for Phase I biotransformation reactions, in which lipophilic drugs and other xenobiotic compounds are converted to more hydrophilic products to facilitate excretion from the body. In the liver, this enzyme contributes to the wide pharmacokinetic variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan. CYP2C9 gene is highly polymorphic. More than 50 single nucleotide polymorphisms (SNPs) have been described in the regulatory and coding regions of the CYP2C9 gene, some of which are associated with reduced enzyme activity compared with wild type in vitro. Extrahepatic CYP2C9 often metabolizes endogenous compounds such as arachidonic acid, 5-hydroxytryptamine, and linoleic acid. ’s EZCypTM 2C9 is a permeabilized and stabilized dried yeast powder preparation containing recombinant human CYP2C9 and recombinant human P450 NADPH oxidoreductase co expressed in the same preparation.

7875 | EZCyp Active Human Cytochrome P450 2C9 DataSheet

Biomolecule/Target: EZCyp™ Active Human CYP2C9

Synonyms: Cytochrome P450 2C, Cytochrome P450 2C9, Cyt2C9, CYPIIC, CYPIIC9, Cyp2c, Microsomal cytochrome P450 2C9, active CYP2C9, human cyp2c9, human CYP2C9, recombinant CYP2C, CPC9, CYP2C, CYP2C10, CYPIIC9, P450IIC9

Alternates names: Vascular Endothelial Growth Factor-C, VEGFC, Flt4 ligand

Taglines: Unique, cost-effective CYP2C9 catalytic system with active recombinant human CYP2C9 coexpressed with the active NADPH reductase in a semipermeable membrane system.

NCBI Gene ID #: 7424

NCBI Gene Symbol: VEGFC

Gene Source: Human

Accession #: Q6FH59

Recombinant: Yes

Source: Pichia pastoris

Purity by SDS-PAGEs: 90%

Assay: N/A

Purity: NA

Assay #2: NA

Endotoxin Level: NA

Activity (Specifications/test method): K850, Metabolite HPLC

Biological activity: Activity of VEGF-C is tested by the stimulation of VEGF-R3 phosphorylation in cells transfected with VEGF-R3. The expected ED is > 200 ng/ml.

Results: NA

Binding Capacity: NA

Unit Definition: NA

Molecular Weight: 15-16 kDa

Concentration: N/A

Appearance: Dry powder

Physical form description: Lyophilized powder

Reconstitution Instructions: Reconstitute in 0.1% acetic acid to a concentration of 0.1-1.0 mg/ml

Amino acid sequence: N/A